There are some serious questions that should probably be asked. How much did Affymax management know about the risks? What were the financial incentives and bonuses for ignoring probability of deaths? Since it was known that this drug caused deaths in non-dialysis setting, then why was it assumed that the dialysis procedure itself would stop the drug from killing patients? Was this just a case of inept management, or did the financial incentives stop them from protecting patients.